Comparison of the relative inhibitory activity of HIG-82-IL-1Ra+ cells to recombinant IL-1Ra when added to HSF cultures 24 hours before stimulation with IL-1β

Copyright information:Taken from "A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer"Arthritis Research & Therapy 2003;5(5):R301-R309.Published online 1 Aug 2003PMCID:PMC193732.Copyright © 2003 Gouze et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. As in Fig. , HSF were plated in multiwell plates and incubated with a range of doses of rIL-1Ra or HIG-82-IL-1Ra+ cells. Twenty-four hours following the addition of the protein or cells, 5 ng recombinant IL-1β was added, and the cultures were incubated an additional 48 hours. PGEproduction at 48 hours after IL-1stimulation for the IL-1Ra treated groups was normalized to control, namely IL-1 stimulated HSF cultures that did not receive IL-1Ra. Shown in the graph is the relationship between PGEproduction at48 hours after IL-1 stimulation, and IL-1Ra concentration immediately before and 48 hours after IL-1 stimulation. PGE/IL-1Ra levels for cultures receiving the IL-1Ra producing cells are represented by triangles; black indicates before IL-1 stimulation and white indicates 48 hours after. The shaded boxes represent the PGE/IL-1Ra levels for cultures receiving recombinant IL-1Ra. A single set of data points is shown for the wells receiving the recombinant protein because the IL-1Ra concentration did not change over time. The shaded region between the curves is shown to emphasize the change in IL-1Ra levels over time in the wells receiving the IL-1Ra producing cells. Experiments were performed in triplicate, and each data point repesents the mean value ± SD. HSF, human synovial fibroblast; IL-1Ra, IL-1 receptor antagonist; PGE, prostaglandin E.